On October 25, 2024, Homburger advised Molecular Partners, a clinical-stage biotechnology company, in the announcement of the pricing of an underwritten public offering. The offering consisted of 3,642,988 American Depositary Shares (ADSs), representing new shares, priced at $5.49 per
Tags :Romain Fakhoury
Evolva Holding announced that it had entered into a new agreement with Nice & Green (N&G) to replace an existing an equity-linked debt instrument issued by Evolva consisting of convertible notes issued in
Homburger advised allosteric modulation company Addex Therapeutics in Plan-les-Ouates, Geneva (SIX: ADXN) in the completion of an equity financing transaction with a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 7,999,998 shares
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
The controlling shareholder of Reuge, the renowned music box producer, successfully completed the sale of a majority stake in the Reuge manufacture to the Swiss luxury watchmaker De Bethune. The independent watchmaker, known for its
StoneX Group, a global financial services company, announced that it had acquired Cotton Distributors (CDI). CDI operates a global cotton merchant business and is headquartered in Lausanne with an office in Brazil. Homburger advised StoneX
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, has completed a USD 4,2 million equity financing. The allosteric modulation company Addex has entered into a definitive agreement with Armistice Capital, a
Allosteric modulation company Addex Therapeutics has entered into a definitive agreement with Armistice Capital, a healthcare-focused institutional investor, pursuant to which Addex agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares («ADSs») at
Kohlberg Kravis Roberts & Co (KKR), a global investment firm, and Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, have entered into an agreement where KKR will acquire Biosynth Carbosynth
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on the development and commercialisation of innovative medicines for rare neuromuscular neuromuscular and pulmonary diseases with high unmet medical need, has announced an equity financing of CHF 20
